Logo

Biogen's Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP's Positive Opinion to Use During Pregnancy and Breastfeeding

Share this

Biogen's Plegridy (peginterferon beta-1a) and Avonex (interferon beta-1a) Receive CHMP's Positive Opinion to Use During Pregnancy and Breastfeeding

Shots:

  • The CHMP recommended an update to MAA of approved interferon beta treatments (Plegridy & Avonex) to remove pregnancy contraindications and allow them to use during pregnancy and breastfeeding in women with relapsing multiple sclerosis
  • The CHMP positive opinion is based on 1-000+ real-world pregnancy outcomes demonstrating no increased risk of major congenital anomalies after exposure to interferon beta before conception and/or during the first trimester
  • Plegridy (q2w) is subcutaneous pegylated interferon indicated in RRMS while AVONEX is one of the most prescribed treatments for relapsing forms of MS- currently approved in 90+ countries

Click here to­ read full press release/ article

 | Ref: Biogen | Image: Biogen


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions